rich 1.0 Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency. Pharmaceutical Executive https://audioboom.com/channels/5120049-pharmaceutical-executive Audioboom https://audioboom.com 480 95 https://audioboom.com/i/43837514/600x600/c 600 600 <iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8952640/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>